MCID: HML018
MIFTS: 22

Homologous Wasting Disease

Categories: Rare diseases

Aliases & Classifications for Homologous Wasting Disease

MalaCards integrated aliases for Homologous Wasting Disease:

Name: Homologous Wasting Disease 52
Graft-Vs-Host Disease 71

Classifications:



External Ids:

UMLS 71 C0018133

Summaries for Homologous Wasting Disease

MalaCards based summary : Homologous Wasting Disease, is also known as graft-vs-host disease. The drugs Posaconazole and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow.

Related Diseases for Homologous Wasting Disease

Symptoms & Phenotypes for Homologous Wasting Disease

Drugs & Therapeutics for Homologous Wasting Disease

Drugs for Homologous Wasting Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 367, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
4
Histamine Approved, Investigational Phase 4 51-45-6 774
5
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
8
Promethazine Approved, Investigational Phase 4 60-87-7 4927
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
11
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
12
Povidone Approved Phase 4 9003-39-8
13
Simethicone Approved Phase 4 8050-81-5
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Semustine Experimental, Investigational Phase 4 13909-09-6
16
Treosulfan Investigational Phase 4 299-75-2 9296
17 Antiparasitic Agents Phase 4
18 Antiprotozoal Agents Phase 4
19 Thymoglobulin Phase 4
20 Autonomic Agents Phase 4
21 Adjuvants, Immunologic Phase 4
22
Histamine Phosphate Phase 4 51-74-1 65513
23 Antiemetics Phase 4
24 Gastrointestinal Agents Phase 4
25 Protective Agents Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Steroid Synthesis Inhibitors Phase 4
28 Neurotransmitter Agents Phase 4
29 Lubricant Eye Drops Phase 4
30 Anti-Allergic Agents Phase 4
31 Cytochrome P-450 CYP3A Inhibitors Phase 4
32
Hydroxyitraconazole Phase 4
33 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
34 Central Nervous System Depressants Phase 4
35 Hypnotics and Sedatives Phase 4
36 Histamine H1 Antagonists Phase 4
37 Histamine Antagonists Phase 4
38 Anti-Ulcer Agents Phase 4
39 Plasma Substitutes Phase 4
40 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
41 Viscosupplements Phase 4
42 Emollients Phase 4
43 Blood Substitutes Phase 4
44 Antacids Phase 4
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
48
Carmustine Approved, Investigational Phase 2, Phase 3 154-93-8 2578
49
Hydroxychloroquine Approved Phase 3 118-42-3 3652
50
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
51
Acyclovir Approved Phase 3 59277-89-3 2022
52
Idarubicin Approved Phase 3 58957-92-9 42890
53
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
54
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
55
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
56
Pegaspargase Approved, Investigational Phase 3 130167-69-0
57
Sodium citrate Approved, Investigational Phase 3 68-04-2
58
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
59
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
60
Hydroxyurea Approved Phase 3 127-07-1 3657
61
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
62
Peginterferon alfa-2b Approved Phase 2, Phase 3 215647-85-1, 99210-65-8
63
Daunorubicin Approved Phase 3 20830-81-3 30323
64
Protein C Approved Phase 3
65
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
66
Etoposide Approved Phase 3 33419-42-0 36462
67
Methoxsalen Approved Phase 3 298-81-7 4114
68
Mesna Approved, Investigational Phase 3 3375-50-6 598
69
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
70
carbamide peroxide Approved Phase 3 124-43-6
71
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
72
Cysteine Approved, Nutraceutical Phase 3 52-90-4 5862
73 Ophthalmic Solutions Phase 3
74 Anti-Asthmatic Agents Phase 3
75 Respiratory System Agents Phase 3
76 Bronchodilator Agents Phase 3
77 BB 1101 Phase 3
78 Analgesics Phase 3
79 Paraproteins Phase 3
80 Myeloma Proteins Phase 3
81 Immunoglobulin Idiotypes Phase 3
82 Antimalarials Phase 3
83 Interferon-gamma Phase 3
84 Antimitotic Agents Phase 3
85
asparaginase Phase 3
86 Janus Kinase Inhibitors Phase 3
87 Acidophilus Phase 3
88 Citrate Phase 3
89 Anticoagulants Phase 3
90 interferons Phase 2, Phase 3
91 Interferon-alpha Phase 2, Phase 3
92 Interferon alpha-2 Phase 2, Phase 3
93 Gemtuzumab Phase 3
94 Coagulants Phase 3
95 Pharmaceutical Solutions Phase 3
96
Beclomethasone Phase 3 4419-39-0 20469
97 Antineoplastic Agents, Hormonal Phase 3
98
protease inhibitors Phase 2, Phase 3
99 HIV Protease Inhibitors Phase 2, Phase 3
100 Serine Proteinase Inhibitors Phase 2, Phase 3
101 Alpha 1-Antitrypsin Phase 2, Phase 3
102 Trypsin Inhibitors Phase 2, Phase 3
103 Protein C Inhibitor Phase 2, Phase 3
104 Etoposide phosphate Phase 3
105 Topoisomerase Inhibitors Phase 3
106 Photosensitizing Agents Phase 3
107 Immunoglobulin G Phase 3
108
Bilirubin Phase 3 635-65-4, 69853-43-6 5280352 21252250
109 N-monoacetylcystine Phase 3
110
Serine Investigational, Nutraceutical Phase 2, Phase 3 56-45-1 5951
111
Foscarnet Approved Phase 2 4428-95-9, 63585-09-1 3415
112
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454
113
Furosemide Approved, Vet_approved Phase 1, Phase 2 54-31-9 3440
114
Ustekinumab Approved, Investigational Phase 2 815610-63-0
115
Pomalidomide Approved Phase 2 19171-19-8
116
Maraviroc Approved, Investigational Phase 2 376348-65-1 3002977
117
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
118
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
119
Granisetron Approved, Investigational Phase 2 109889-09-0 3510
120
Azathioprine Approved Phase 2 446-86-6 2265
121
Montelukast Approved Phase 2 158966-92-8 5281040
122
Micafungin Approved, Investigational Phase 2 235114-32-6 3081921 477468
123
Iodine Approved, Investigational Phase 2 7553-56-2 807
124
Ethanol Approved Phase 2 64-17-5 702
125
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
126
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
127
Benzyl alcohol Approved Phase 2 100-51-6 244
128
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
129
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
130
Defibrotide Approved, Investigational Phase 2 83712-60-1
131
tannic acid Approved Phase 2 1401-55-4
132
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
133
Melphalan Approved Phase 2 148-82-3 4053 460612
134
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
135
Natalizumab Approved, Investigational Phase 2 189261-10-7
136
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
137
Polymyxin B Approved, Vet_approved Phase 2 1404-26-8
138
Vancomycin Approved Phase 2 1404-90-6 441141 14969
139
Blinatumomab Approved, Investigational Phase 2 853426-35-4
140
Atorvastatin Approved Phase 2 134523-00-5 60823
141
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
142
leucovorin Approved Phase 2 58-05-9 6006 143
143
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
144
ofatumumab Approved Phase 1, Phase 2 679818-59-8 6918251
145
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2
146
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
147
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
148
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
149
Pembrolizumab Approved Phase 2 1374853-91-4
150
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560 441411
151
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033